Stock Track | Caris Life Sciences Soars 20.43% in Pre-market on Strong Earnings Beat

Stock Track02-27

Caris Life Sciences Inc's stock surged 20.43% in pre-market trading on Friday, following the release of its quarterly earnings report that significantly exceeded analyst expectations.

The medical equipment company reported adjusted earnings of 8 cents per share for the quarter ended September 30, beating the mean analyst expectation of a loss of 21 cents per share. The company also reported quarterly net income of $81.96 million. While revenue of $216.83 million came in slightly below the $239.03 million analysts had expected, the substantial earnings beat appears to be driving investor optimism.

Analyst sentiment toward the company had been improving prior to the report, with the mean earnings estimate rising approximately 115% over the last three months. The current average analyst rating on the shares remains "buy," with a median 12-month price target of $37.50. Separately, JP Morgan adjusted its price target for Caris Life Sciences to $35 from $40, though this revision appears to have been overshadowed by the positive earnings results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165202995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165202995","market":"nz","top_or_hot":-1,"title":"Stock Track | Caris Life Sciences Soars 20.43% in Pre-market on Strong Earnings Beat","media":"Stock Track","content":"<p>Caris Life Sciences Inc's stock surged 20.43% in pre-market trading on Friday, following the release of its quarterly earnings report that significantly exceeded analyst expectations.</p><p>The medical equipment company reported adjusted earnings of 8 cents per share for the quarter ended September 30, beating the mean analyst expectation of a loss of 21 cents per share. The company also reported quarterly net income of $81.96 million. While revenue of $216.83 million came in slightly below the $239.03 million analysts had expected, the substantial earnings beat appears to be driving investor optimism.</p><p>Analyst sentiment toward the company had been improving prior to the report, with the mean earnings estimate rising approximately 115% over the last three months. The current average analyst rating on the shares remains \"buy,\" with a median 12-month price target of $37.50. Separately, JP Morgan adjusted its price target for Caris Life Sciences to $35 from $40, though this revision appears to have been overshadowed by the positive earnings results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Caris Life Sciences Soars 20.43% in Pre-market on Strong Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Caris Life Sciences Soars 20.43% in Pre-market on Strong Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Caris Life Sciences Inc's stock surged 20.43% in pre-market trading on Friday, following the release of its quarterly earnings report that significantly exceeded analyst expectations.</p><p>The medical equipment company reported adjusted earnings of 8 cents per share for the quarter ended September 30, beating the mean analyst expectation of a loss of 21 cents per share. The company also reported quarterly net income of $81.96 million. While revenue of $216.83 million came in slightly below the $239.03 million analysts had expected, the substantial earnings beat appears to be driving investor optimism.</p><p>Analyst sentiment toward the company had been improving prior to the report, with the mean earnings estimate rising approximately 115% over the last three months. The current average analyst rating on the shares remains \"buy,\" with a median 12-month price target of $37.50. Separately, JP Morgan adjusted its price target for Caris Life Sciences to $35 from $40, though this revision appears to have been overshadowed by the positive earnings results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAI","symbol_name":"Caris Life Sciences, Inc.","start_time":0,"source_url":"","article_id":"1165202995","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165202995","pubTimestamp":1772190923,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Caris Life Sciences Inc's stock surged 20.43% in pre-market trading on Friday, following the release of its quarterly earnings report that significantly exceeded analyst expectations.The medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAI":"Caris Life Sciences, Inc."},"translate_title":"个股追踪|Caris Life Sciences盘前大涨20.43%盈利超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":1},"content_text":"Caris Life Sciences Inc's stock surged 20.43% in pre-market trading on Friday, following the release of its quarterly earnings report that significantly exceeded analyst expectations.The medical equipment company reported adjusted earnings of 8 cents per share for the quarter ended September 30, beating the mean analyst expectation of a loss of 21 cents per share. The company also reported quarterly net income of $81.96 million. While revenue of $216.83 million came in slightly below the $239.03 million analysts had expected, the substantial earnings beat appears to be driving investor optimism.Analyst sentiment toward the company had been improving prior to the report, with the mean earnings estimate rising approximately 115% over the last three months. The current average analyst rating on the shares remains \"buy,\" with a median 12-month price target of $37.50. Separately, JP Morgan adjusted its price target for Caris Life Sciences to $35 from $40, though this revision appears to have been overshadowed by the positive earnings results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165202995","isCrawlerRequest":true}